DT402
Autism Spectrum Disorder (ASD)
Phase 2aActively Recruiting
Key Facts
Indication
Autism Spectrum Disorder (ASD)
Phase
Phase 2a
Status
Actively Recruiting
Company
About Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileTherapeutic Areas
Other Autism Spectrum Disorder (ASD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-210 | SciSparc | Phase II |
| PAX-101 (IV Suramin) | PaxMedica | Phase 3 |
| eTNS Platform | NeuroSigma | Unknown |
| CM-AT | Curemark | Phase 3 |
| ML-004 | MapLight Therapeutics | Phase 1 |